Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Vandana Singh

Pacific Biosciences Shares Fall As Q4 Earnings Miss Estimates

Pacific Biosciences of California Inc (NASDAQ:PACB) reported Q4 sales of $36.02 million, +33% Y/Y, missing the consensus of $36.12 million.

  • The company placed 48 Sequel II or IIe instruments in the quarter, bringing the total installed base to 374, compared to 203 a year ago.
  • Of those total sales, product revenues were $31.17 million, up 32% Y/Y, and service & other revenues were $4.85 million, up 38% Y/Y.
  • Product revenue consisted of $16.2 million in instrument revenue and $15 million in consumables revenue.
  • The gross margin expanded to 47% from 42% a year ago.
  • PacBio's adjusted net loss was $(0.30) per share, compared to $(0.12) per share, in the prior-year period, missing the Wall Street estimate of $(0.28).
  • Cash, cash equivalents, and investments, excluding short and long-term restricted cash, at December 31, 2021, totaled $1.04 billion.
  • The company launched the HiFiViral SARS-CoV-2 Kit, a fully kitted end-to-end solution for COVID-19 surveillance to identify new SARS-CoV-2 variants and detect all circulating variants.
  • Price Action: PACB shares traded lower by 10.5% at $10.19 during pre-market trading on Wednesday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.